Study S001640

Central Nervous System Effects of Liraglutide® 3.0 mg on Reward Mechanisms in Obese Patients Without Diabetes, in Relation to Food Addiction. A Randomized, Single-centre, Double-blind, Placebo Controlled Clinical Trial.

ClinicalTrials.gov record

Registration

Registration: NCT03347890
Acronym: LIRAOB
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 70
Start: 2018-03-05
Primary completion: 2020-03-18
Lead sponsor: Zoltan Pataky
Conditions: Obesity
Interventions: DRUG:Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: REGISTRY:U1111-1194-9675; NIH:2017

Registered primary outcomes

Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system [16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.